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Abstract. 
 
The mitogen-activated protein (MAP) kinase 
pathway is a critical regulator of cell growth, migration, 
and differentiation. Growth factor activation of MAP 
kinase in NIH 3T3 cells is strongly dependent upon in-
tegrin-mediated adhesion, an effect that contributes to 
the anchorage dependence of normal cell growth. We 
now show that expression of constructs that constitu-
tively activate focal adhesion kinase (FAK) rescued the 
defect in serum activation of MAP kinase in suspended 
cells without directly activating MAP kinase. Dominant 
negative FAK blocked both the rescue of suspended 
cells by the activated construct and the serum activa-
tion of MAP kinase in adherent cells. MAP kinase in 
FAK
 
2
 
/
 
2
 
 mouse embryo ﬁbroblasts was adhesion-insen-
sitive, and reexpression of FAK restored its adhesion 
dependence. MAP kinase activity in 
 
ras
 
-transformed 
cells is still decreased in suspension, but expression of 
constructs that constitutively activate FAK enhanced 
their anchorage-independent growth without increas-
ing adherent growth. V-
 
src
 
, which activates both Ras 
and FAK, induced MAP kinase activation that was in-
sensitive to loss of adhesion, and that was blocked by a 
dominant negative FAK. These results demonstrate 
that FAK mediates the integrin requirement for serum 
activation of MAP kinase in normal cells, and that by-
passing this mechanism contributes to anchorage-inde-
pendent growth in transformed cells.
Key words: growth factor regulation • signal trans-
 
duction • anchorage independence • src transformation • 
cancer
 
M
 
ITOGEN
 
-
 
ACTIVATED
 
 protein (MAP)
 
1
 
 kinases, also
known as Erks 1 and 2 (for extracellular-regu-
lated kinases), control many cellular responses
including proliferation, migration, and differentiation (for
reviews see Crews and Erikson, 1993; Blumer and John-
son, 1994; M.H. Cobb et al., 1994; Johnson and Vaillancourt,
1994; Marshall, 1995). The MAP kinase pathway is stimu-
lated by soluble growth factors and cytokines, and in some
cases by cell adhesion to extracellular matrix (ECM) pro-
teins (Chen et al., 1994; Morino et al., 1995; Zhu and As-
soian, 1995). Normal cell growth requires stimulation by
both growth factors and adhesion to the ECM. We and
others have reported that growth factor activation of the
MAP kinase pathway requires cell adhesion (Cybulsky et
al., 1994; Inoue et al., 1996; Miyamoto et al., 1996; Cybul-
sky and McTavish, 1997; Lin et al., 1997b; Renshaw et al.,
1997). Adding serum or growth factors to nonadherent
cells triggers robust activation of early components of the
pathway such as Ras, but activation of Raf or MEK1 is
substantially diminished (Lin et al., 1997; Renshaw et al.,
1997). This effect is distinct from the transient induction of
MAP kinase activity when suspended cells are replated on
ECM proteins, which involves integrin activation of Ras
(Chen et al., 1994; Schlaepfer et al., 1994). We also showed
that the effect is specifically mediated by integrins (Ren-
shaw et al., 1997).
Focal adhesion kinase (FAK) is a nonreceptor tyrosine
kinase that is ubiquitously expressed throughout develop-
ment (Furuta et al., 1995), and is widely expressed in ad-
herent cell types in culture (Kornberg et al., 1992; Matsu-
moto et al., 1994; Zhang et al., 1994). Its phosphorylation
and kinase activity are closely regulated by integrin-medi-
ated cell adhesion (Kanner et al., 1990; Guan and Shallo-
way, 1992), suggesting that FAK may be an important me-
diator of integrin signaling. Deletion of FAK from the
mouse genome leads to an early embryonic lethal pheno-
type indicative of a defect in gastrulation. Cells from
FAK
 
2
 
/
 
2
 
 mice show decreased migration, which is consis-
tent with deficient gastrulation. Other major defects in-
clude impaired vasculogenesis and angiogenesis. The over-
all phenotype of the FAK
 
2
 
/
 
2
 
 mouse is similar to the
fibronectin (FN
 
2/2
 
) mouse (George et al., 1993), support-
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ing the hypothesis that FAK lies on an integrin signaling
pathway.
FAK has been implicated in cell migration (Ilic et al.,
1995; Cary et al., 1996; Gilmore and Romer, 1996), growth,
and survival (Furuta et al., 1995; Frisch et al., 1996;
Gilmore and Romer, 1996; Hungerford et al., 1996). It has
been shown to bind a variety of adapter and signaling mol-
ecules including paxillin (Turner and Miller, 1994), src
family kinases (Cobb et al., 1994; Schlaepfer et al., 1994),
p130cas (Polte and Hanks, 1995), PI 3-kinase (Chen and
Guan, 1994), and GRB2 (Schlaepfer et al., 1994). How-
ever, there is little information available concerning spe-
cific biochemical pathways that mediate cellular effects of
FAK. FAK has been proposed to mediate the transient
integrin-dependent activation of MAP kinase when sus-
pended cells are replated on ECM proteins such as FN
(Chen et al., 1994; Schlaepfer et al., 1994; Schlaepfer and
Hunter, 1997). This pathway was reported to involve
GRB2 binding to phosphorylated FAK, followed by re-
cruitment of SOS, and activation of 
 
ras
 
. However, other
groups showed that activation of MAP kinase by adhesion
to ECM does not correlate with FAK phosphorylation
(Wary et al., 1996; Lin et al., 1997). Furthermore, FAK
 
2
 
/
 
2
 
fibroblasts still show integrin activation of MAP kinase
upon replating (Sieg et al., 1998). It seems likely that FAK
can contribute to the direct integrin activation of MAP ki-
nase in replated cells under some experimental conditions,
but that there are other pathways that make FAK nones-
sential.
We have examined the role of FAK, not in the transient
integrin-dependent activation of MAP kinase that occurs
upon replating of cells on ECM proteins, but in the inte-
grin requirement for growth factor activation of MAP ki-
nase in stably adherent cells. Our data show that FAK ac-
tivity is both necessary and sufficient for the integrin
enhancement of growth factor induction of the MAP ki-
nase pathway. Our results also define the role of FAK in
oncogenic transformation by 
 
v-src
 
.
 
Materials and Methods
 
Reagents and Plasmids
 
DME, calf serum, and Lipofectamine were purchased from GIBCO BRL.
FBS was purchased from Gemini Bio-Products Inc. Myelin basic protein
was prepared from spinal cord (Pelfreeze) as previously described
(Deibler et al., 1972). Methyl cellulose, agarose, and all other reagents
were purchased from Sigma Chemical Co. unless otherwise specified. The
plasmids CMV5 HA-ERK2 (Renshaw et al., 1996), IL2R
 
b
 
1, IL2R
 
b
 
3 (Ak-
iyama et al., 1994; LaFlamme et al., 1994), CD2FAK, CD2FAK K454R,
CD2FAK Y397F (Chan et al., 1994), FRNK and pcDNA3 FAK wt (Sieg
et al., 1998), pDCR 
 
ras
 
 G12V, and RSV Hyg (Renshaw et al., 1997) are as
described. The src construct containing an activating point mutation at ty-
rosine 527 was obtained from Dr. Jean Wang (University of California,
San Diego).
 
Cell Culture and Transfection
 
NIH 3T3 cells were cultured in DME supplemented with 10% bovine calf
serum. FAK
 
1
 
/
 
1
 
 and FAK
 
2
 
/
 
2
 
 mouse embryo fibroblasts (MEFs) were cul-
tured in DME supplemented with 10% FBS. For transfections, cells were
plated at a density of 4 
 
3
 
 10
 
5
 
 cells per 6-cm dish 24 h before transfection.
Cells were transfected with Lipofectamine (GIBCO BRL) as previously
described (Renshaw et al., 1997). 24 h after transfection, cells were trans-
ferred to medium containing 0.5% serum for an additional 24 h for adher-
ent cells. Cells that were suspended for 24 h were trypsinized 24 h after
transfection and placed in suspension in DME media containing 0.5%
methyl cellulose, 0.4% serum over 1% agar-coated dishes as previously
described (Renshaw et al., 1997). Cells were stimulated by the addition of
serum to 10% for 10 min, extracted in lysis buffer (Renshaw et al., 1997),
and assayed for Erk2 and MEK 1 activity.
 
Transformation
 
For transformation assays, cells were transfected using Lipofectamine
with 0.4 
 
m
 
g of RSVHyg and 0.8 
 
m
 
g of two different cDNAs to give 2.0 
 
m
 
g
total DNA. Vectors were the empty control vector, pDCR 
 
ras
 
 G12V,
IL2
 
b
 
1, and CD2FAK. After 24 h, the cells were fed fresh medium and al-
lowed to grow for 2 d. Cells were trypsinized and 1/20
 
 
 
of the total was re-
plated in either normal growth medium, minimal medium, or soft agar to
measure foci formation as previously described (Renshaw et al., 1997).
Cells were also replated in medium containing 200 
 
m
 
g/ml Hygromycin B
(Boehringer Mannheim) to measure transformation efficiency. Soft agar
colony volume was determined by visually measuring colony diameter
against a scale, and then calculating the volume according to the formula,
V
 
 5 
 
4/3
 
p
 
r
 
3
 
. Minimal media foci size was determined by trypsinizing the
foci and replating them in soft agar. The number of soft agar colonies
were counted after 2 wk to determine the number of transformed cells per
original minimal medium focus.
 
Measurement of Erk 2 Activity
 
For assays of transfected hemagglutinin-tagged (HA) Erk2 activity, anti–
HA (12CA5) antibody purified over an HA peptide affinity column was
used for immunoprecipitations. Erk activities were immunoprecipitated
from 150 
 
m
 
g of cell lysates using 0.5 
 
m
 
g of anti–HA antibody. For all as-
says, Erk activation was normalized to the amount of Erk2 protein immu-
noprecipitated. One third of each immunoprecipitation was run on a 10%
SDS–polyacrylamide gel that was transferred to Hybond C (Amersham)
and immunoblotted using the anti–Erk2 antibody (C-14; Santa Cruz Bio-
technology) to measure the amount of Erk2 protein. The remaining two
thirds were used to measure Erk2 activity to measure the in-gel kinase as-
say as described (Renshaw et al., 1997). Activities of endogenous Erks 1
and 2 from FAK
 
1
 
/
 
1
 
 and FAK
 
2
 
/
 
2
 
 MEFs were measured by running 5 
 
m
 
g of
total cell lysate on gels for assay by the in-gel kinase assay method. In
brief, samples were run on 12.5% SDS–polyacrylamide gels containing
0.25 mg/ml myelin basic protein and renatured. Kinase reactions were per-
formed soaking gels in kinase buffer (Kamashita and Fujisawa, 1989) con-
taining 25 
 
m
 
Ci/ml 
 
g
 
-[
 
32
 
P]ATP and 10 
 
m
 
M cold ATP. Gels were washed ex-
haustively and analyzed by autoradiography. Autoradiographs were
quantitatively analyzed using a model I.S. 1000 digital imaging system
from Alpha-Innotech Corp.
 
Measurement of MEK 1 Activity
 
Endogenous MEK-1 was immunoprecipitated from 100 
 
m
 
g of cell lysate
using anti–MEK-1 (Santa Cruz Biotechnology). Immunoprecipitates were
washed three times in lysis buffer and once in kinase buffer (Chen et al.,
1996), 10 mM Tris, pH 7.5, 10 mM MgCl
 
2
 
, and 1 mM DTT. One fifth of the
samples were used to measure the amount of MEK-1 protein by Western
blotting, four fifths were used for kinase assays. MEK kinase activity was
measured in kinase buffer containing 25 
 
m
 
M ATP, 5 
 
m
 
Ci 
 
g
 
-ATP, and 2 
 
m
 
g
of kinase-dead GST-ERK2 (Hipskind et al., 1994), for 30 min at room
temperature. Samples were electrophoresed on 10% SDS–polyacrylamide
gels, which were dried and analyzed by autoradiography.
 
Results
 
Restoration of MAP Kinase Activation in Suspension
 
Our strategy for identifying components of the pathway
that mediates the integrin requirement for growth factor
activation of MAP kinase was to screen for activated mu-
tants that could specifically restore MAP kinase in sus-
pended cells. As an initial test of the strategy, HA-tagged
Erk2 was coexpressed with a chimera that contains the cy-
toplasmic tail of the integrin 
 
b
 
1 subunit fused to the extra-
cellular and transmembrane domain of the Tac subunit of 
Renshaw et al. 
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the IL-2 receptor (IL2R
 
b
 
1) (Akiyama et al., 1994). This
chimera induces FAK phosphorylation in suspended cells,
indicating that it signals constitutively (Akiyama et al.,
1994). Previous work showed that cellular responses to se-
rum or the purified mitogen platelet–derived growth fac-
tor or lysophosphatidic acid were similarly modulated by
cell adhesion (Renshaw et al., 1997). Thus, cells were stim-
ulated with 10% serum for convenience, and because it
mimics normal culture conditions.
When cotransfected with a control plasmid, the activity
of the transiently transfected HA-Erk2 was strongly stim-
ulated by serum in adherent cells, but was minimal in sus-
pended cells (Fig. 1). This behavior mimics the endoge-
nous MAP kinase (Renshaw et al., 1997), indicating that
the transfected Erk is regulated normally. By contrast,
cells cotransfected with HA-Erk2 and IL2R
 
b
 
1 showed
strong activation in both the adherent and suspended cells.
Expression of IL2R
 
b
 
3 also rescued serum induction of
MAP kinase activity in suspension, but expression of an
IL2
 
a
 
5 construct had no effect (not shown). Neither
IL2R
 
b
 
1 nor IL2R
 
b
 
3 directly induced Erk activity in the
absence of serum or altered its activation in adherent cells.
These results show that a constitutively activated integrin
 
b
 
1 cytoplasmic tail can substitute for cell adhesion and
specifically restore serum activation of MAP kinase in sus-
pended cells.
 
FAK Activity Mediates the Integrin Signal
 
The IL2R
 
b
 
1 construct induces phosphorylation of FAK in
suspended cells (Akiyama et al., 1994; Lukashev et al.,
1994); thus, FAK was an obvious candidate to mediate this
effect. To test if FAK was involved, a FAK chimera
(CD2FAK) that has constitutively high kinase activity
(Chan et al., 1994) was coexpressed with the HA-tagged
Erk2 construct. Expression of CD2FAK also completely
restored serum activation of Erk2 in suspended cells (Fig.
2), but like the IL2R
 
b
 
1, did not directly activate MAP ki-
nase in the absence of serum or alter activation of Erk2 in
adherent cells. Kinase-defective CD2FAK (K454R) had
no effect on MAP kinase, indicating that tyrosine kinase
activity is required.
It is well established that activity of endogenous FAK is
regulated by integrin-mediated adhesion (Guan and Shal-
loway, 1992; Lipfert et al., 1992; Schaller et al., 1992),
though soluble mitogens also stimulate FAK in some sys-
tems (Zachary et al., 1992; Rankin et al., 1996). We also
observed that kinase activity of FAK immunoprecipitated
Figure 1. IL2Rb1 restores the serum induction of MAP kinase in
suspended cells. (a) NIH 3T3 cells were cotransfected with HA-
Erk2 and either IL2b1 or empty control vector. Activity of the
immunoprecipitated HA-Erk2 was measured from both adher-
ent or suspended cells that were starved for 24 h in 0.5% serum
(2), or stimulated with 10% serum for 10 min (1). The amount
of immunoprecipitated HA-Erk2 protein was determined by
Western blotting. (b) Quantitation of the Erk kinase assays is
shown graphically. Values are normalized to Erk protein levels
and represent the means 6 SDs from four independent experi-
ments.
Figure 2. Restoration of MAP kinase activation by constitutively
active FAK. (a) Activity of transfected MAP kinase was mea-
sured as in Fig. 1, in 3T3 cells cotransfected with HA-Erk2 and
either constitutively active FAK (CD2FAK) or the kinase-dead
variant (CD2FAK K454R). (b) The means 6 SDs for specific ki-
nase activity (normalized to protein level) were quantitated from
three independent experiments. 
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from adherent 3T3 cells was much higher than from sus-
pended cells, and that addition of serum caused only a
slight increase in either case (data not shown). Western
blotting of whole cell lysates indicated no change in the
levels of FAK or appearance of proteolytic fragments af-
ter 24 h in suspension (data not shown). These results are
in agreement with published data and support the idea
that FAK is regulated by cell adhesion.
Next, we tested whether FAK was required for the ef-
fect of integrins on this pathway. HA-Erk2 was coex-
pressed with the FAK tyrosine autophosphorylation mu-
tant (CD2FAK Y397F) or the COOH terminus of FAK,
termed FRNK, both of which have been shown to function
as dominant negatives (Gilmore and Romer, 1996; Rich-
ardson and Parsons, 1996; Richardson et al., 1997). These
mutants were tested for their ability to block effects of the
IL2
 
b
 
1 chimera and the endogenous integrins that bind to
ECM in adherent cells in culture. Results from these ex-
periments showed that the Y397F FAK mutant blocked
activation of MAP kinase in adherent cells by 80% (Fig. 3,
a and b). A similar result (79% inhibition) was obtained
using the dominant negative FAK construct, FRNK.
Dominant negative FAK also blocked the rescue of Erk2
activity by IL2
 
b
 
1 in suspended cells (Fig. 3, c and d). These
results demonstrate that the integrin-dependent signal that
promotes serum activation of MAP kinase requires FAK.
 
MAP Kinase in FAK
 
2
 
/
 
2
 
 Cells Is Adhesion-insensitive
 
To test the role of FAK in this pathway without relying on
overexpression of mutant proteins, we examined adherent
and suspended polyclonal fibroblasts from FAK
 
2
 
/
 
2
 
 mouse
 
embryos. FAK-positive MEFs behave similarly to 3T3
cells in that the activation of MEK 1, Erk1, and Erk2 was
strongly dependent on cell adhesion (Fig. 4). By contrast,
the FAK
 
2
 
/
 
2
 
 cells showed no adhesion dependence for the
activation of the MAP kinase pathway. The absolute level
of kinase activation in the FAK
 
2
 
/
 
2
 
 cells was lower than in
FAK
 
1
 
/
 
1
 
 cells, equivalent to 46% for MEK1 and 61% for
Erk activity relative to FAK
 
1
 
/
 
1
 
 cells. However, the base-
line for MAP kinase activity in the FAK
 
2
 
/
 
2
 
 cells in the ab-
sence of serum was 72% higher than in FAK
 
1
 
/
 
1
 
 cells;
serum induction of MAP kinase activity was, therefore,
3.4-fold in FAK
 
2
 
/
 
2
 
 cells compared with 9.5-fold in FAK
 
1
 
/
 
1
 
cells. Importantly, no reduction in the activation of MEK
or Erks occurred when the FAK
 
2
 
/
 
2
 
 cells were placed in
suspension. Thus, although these cells may have partially
adapted for the loss of FAK, they have completely lost the
adhesion dependence for the regulation of MAP kinase by
serum. We also noted that Raf in both FAK
 
1
 
/
 
1
 
 
 
and FAK
 
2
 
/
 
2
 
cells showed a strong gel shift upon addition of serum, in-
dependent of whether cells were adherent or suspended
(not shown). These results agree with our previous data
showing that adhesion acts at the step between Raf and
MEK (Renshaw et al., 1997).
To confirm that FAK was responsible for these differ-
ences, FAK
 
2
 
/
 
2
 
 cells were transiently cotransfected with
wild-type (wt) FAK and HA-Erk2. Expression of wt FAK
in the FAK
 
2
 
/
 
2
 
 cells completely restored the adhesion de-
pendence for the activation of the HA-Erk2, whereas
cotransfection with empty vector had no effect (Fig. 5).
These data demonstrate that FAK is absolutely required
for the adhesion dependence of MAP kinase activation by
serum.
Figure 3. Inhibition of MAP
kinase by dominant negative
FAK. (a) HA-Erk2 kinase ac-
tivity was measured in stably
adherent cells cotransfected
with HA-Erk2 and either
CD2FAK Y397F, FRNK, or
the control vector. Cells were
starved for 24 h in low serum
(2) or starved, and then stim-
ulated with 10% serum (1).
(b) Bar graphs depict the
means and SDs of data from
at least three independent ex-
periments. (c) HA-Erk2 ki-
nase activity was measured in
suspended cells cotransfected
with HA-Erk2 and either the
control vector, IL2Rb1, or
IL2Rb1 in combination with
CD2FAK Y397F. (d) Graphs
depict the means 6 range
from two experiments. 
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FAK Promotes Anchorage-independent Growth
 
The ability of the IL2R
 
b
 
1 and CD2FAK chimeras to main-
tain serum activation of MAP kinase in suspended cells
suggests that these constructs should promote anchorage-
independent growth. Our previous work showed that on-
cogenic V12 
 
ras
 
 strongly activates MAP kinase, but that
this activation is still dramatically decreased in suspended
cells (Renshaw et al., 1997). Thus, increasing MAP kinase
in suspended 
 
ras
 
-transformed cells should enhance colony
formation in semisolid medium. To test this hypothesis,
 
ras
 
 G12V was cotransfected with either active FAK
(CD2FAK) or with the IL2R
 
b
 
1 construct. Cell growth was
assayed under adherent and nonadherent conditions (Ta-
bles I and II). Expression of IL2R
 
b
 
1 or CD2FAK did not
increase the number of 
 
ras
 
 transformants (foci), consistent
with the idea that activated 
 
ras
 
 transforms cells with high
efficiency (White et al., 1995) (Table I.) Nor were these
constructs sufficient to induce anchorage independence or
foci in low serum in the absence of 
 
ras
 
, which is consistent
with data showing that activation of MAP kinase alone
transforms cells very poorly (Khosravi-Far et al., 1995;
White et al., 1995). However, cotransfection of CD2FAK
or IL2R
 
b
 
1 enhanced the growth rate of 
 
ras
 
-transformed
cells in suspension (Table II.). Importantly, this effect oc-
curred without altering growth of adherent 
 
ras
 
-trans-
formed cells, where endogenous integrins already promote
MAP kinase activation by serum. These data are con-
sistent with the hypothesis that these constructs specifi-
cally enhance anchorage-independent growth by allowing
transforming 
 
ras
 
 to activate the MAP kinase pathway to
its full potential in nonadherent cells.
 
FAK in Transformation by v-src
 
FAK was originally identified as a protein whose tyrosine
phosphorylation increased in v-src transformed cells (Kan-
ner et al., 1990). Furthermore, oncogenic src was shown to
stimulate FAK activity in both adherent and suspended
Figure 4. MAP kinase activation is adhesion-insensitive in
FAK2/2 cells. (a) Activation of endogenous MEK-1 and Erks 1
and 2 was measured in both stably adherent and suspended
FAK1/1 and FAK2/2 MEFs. (b) Graphs depict the means 6 SDs
for endogenous MEK-1 kinase activity normalized to protein
levels from at least three experiments. (c) Graphs represent
means 6 SD from three experiments measuring endogenous
Erks 1 and 2 activation normalized to protein level.
Table I. Stable Transformation Assay
Vectors HygR Foci in 10% CS Foci in 0.5% CS
Soft agar
colonies
Control 1,190 6 137 0 6 00  6 00  6 0
Ras 1,217 6 93 1,598 6 56 1,472 6 83 1,481 6 29
IL2Rb1 1,053 6 64 0 6 00  6 00  6 0
Ras1IL2Rb1 1,095 6 80 1,417 6 15 1,338 6 55 1,325 6 40
CD2FAK 1,137 6 129 0 6 00  6 00  6 0
Ras1CD2FAK 1,213 6 110 1,080 6 246 1,078 6 314 1,030 6 320
NIH 3T3 cells were cotransfected with RSVHyg and combinations of the plasmids for
Ras G12V, IL2Rb1, CD2FAK, or empty control vector. Total DNA was kept con-
stant. Cells were trypsinized 2 d after transfection and replated in media containing
10% CS with 200 mg/ml hygromycin B, 10% CS, 0.5% CS, or soft agar to measure
foci and colony formation. Values are means 6 SD from three separate experiments
representing the total number of foci or colonies calculated for the entire transfection.
Table II. Soft Agar and Minimal Medium Colony Size
Vectors
Soft agar Foci in 0.5% CS
Colony volume* Relative Foci size‡ Relative
Ras 0.29 6 0.08 1.00 93 6 6 1.00
Ras1IL2Rb1 1.84 6 0.01 6.23 87 6 7 0.94
Ras1CD2FAK 1.49 6 0.03 5.07 95 6 7 1.02
Transfections from Table I were further analyzed by measuring the soft agar colony
diameter and calculating (4/3pr3) the volume (3 1022 mM3)*. Values represent the
average from two independent experiments in which 15 colonies were measured for
each transfection combination. ‡Minimal medium foci size was determined by
trypsinization followed by replating in soft agar to determine the number of trans-
formed cells per minimal media foci. Values represent the average of two experiments
in which at least 40 foci from each transfection were trypsinized.The Journal of Cell Biology, Volume 147, 1999 616
cells (Guan and Shalloway, 1992). Transforming variants
of src also induce activation of endogenous ras (Gibbs et al.,
1990). These results suggest the interesting prediction that
by activating both FAK and Ras, v-src might efficiently
promote activation of MAP kinase in suspended cells.
Thus, to further test the role of FAK in transformation,
the activity of MAP kinase in cells transfected with acti-
vated src was assayed. These experiments showed that
MAP kinase activity in suspended src-expressing cells was
96 6 4% of that in adherent cells, compared with 16 6 2%
for suspended ras-transfected cells (n 5 4). Thus, anchor-
age-independent activation of FAK correlates with an-
chorage-independent activation of MAP kinase.
To determine if FAK activity was required for the adhe-
sion-independent activation of MAP kinase by activated
src, we cotransfected src and HA-Erk2 along with either a
dominant negative FAK (FRNK) or an empty control vec-
tor. Coexpression of dominant negative FAK inhibited
Erk2 activation in the src-transfected cells by 60–70% in
either suspended or adherent cells (Fig. 6). Consistent
with our results in which FRNK inhibited the serum acti-
vation of MAP kinase in adherent cells, coexpression of
FRNK also strongly inhibited ras activation of MAP ki-
nase in adherent cells, but had only a weak effect in sus-
pended ras cells. We also tested whether colony formation
was inhibited when src was cotransfection with the FRNK
construct. However, no decrease in soft agar growth was
observed (data not shown). This result may demonstrate
that FAK is not essential to transformation by activated
src, or may only indicate that inhibitory levels of FRNK
are difficult to achieve in stable cotransfectants.
Discussion
First, our data demonstrate that the integrin signal that
mediates the serum activation of the MAP kinase pathway
emanates from the b cytoplasmic domain of the integrin
receptor. This conclusion is based on the result that an ac-
tivated IL2Rb1 chimera containing only the cytoplasmic
domain from the integrin was sufficient to restore MAP
kinase in suspended cells. However, this construct did
not induce serum-independent MAP kinase activity. Thus,
the contributions of integrins and growth factor recep-
tors to the MAP kinase pathway can be separated, and
the IL2Rb1 activates only the integrin component of the
pathway.
Second, we found that this integrin signal is mediated by
FAK. Expression of the IL2Rb1 chimera, which was pre-
viously shown to induce FAK phosphorylation (Akiyama
et al., 1994; Lukashev et al., 1994), restored activation of
MAP kinase in suspended cells. Consistent with this result,
Figure 6. v-src activation of MAP kinase is dependent upon
FAK. (a) NIH 3T3 cells were cotransfected with HA-Erk2 and
either active src (pSrcII) or ras G12V in combination with FRNK
or the empty control vector. MAP kinase activity was measured
in both adherent and suspended cells in low serum. (b) Bar
graphs depict the means 6 range from two experiments. Kinase
activity is normalized to Erk2 protein levels.
Figure 5. Reconstitution of FAK2/2 cells. (a) FAK2/2 cells were
cotransfected with HA-Erk2 and either the control vector or wt
FAK. Activation of HA-Erk2 and protein levels were measured
in adherent and suspended cells as for Fig. 1. (b) Graphs display
the mean 6 SD of kinase activity normalized to protein levels
from three independent experiments.Renshaw et al. FAK in Growth Factor Activation of MAP Kinase 617
we found that expression of a constitutively active FAK
was also sufficient to restore MAP kinase induction in sus-
pension. Conversely, dominant negative FAK constructs
inhibited the activation of MAP kinase induced by serum
in adherent cells or the rescue by IL2Rb1 in suspended
cells. These conclusions were confirmed in FAK2/2 MEF
cells, which showed a complete loss of the effect of cell ad-
hesion. Expression of FAK restored the integrin regula-
tion of MAP kinase induction by serum in FAK2/2 cells,
indicating that the differences in FAK2/2 cells were not
due to secondary genetic alterations. These results are all
the more surprising in light of recent findings that FAK is
not essential for the transient activation of MAP kinase
that occurs when suspended cells are replated on FN or
other ECM proteins (Wary et al., 1996; Lin, 1997a; Sieg et
al., 1998). Therefore, these results suggest that FAK may
be more crucial for the synergism with growth factor in-
duction of MAP kinase than it is for the direct integrin in-
duction of MAP kinase activity. However, it should be
noted that the experimental conditions employed for these
published studies of direct integrin activation of Erk differ
from ours in some respects. FAK is activated by a variety
of ECM proteins that bind different integrins, suggesting
that the effect we describe here should relatively wide-
spread, so that many different matrices can promote
growth factor activation of MAP kinase. However, we
have not compared different ECM proteins for their po-
tency in this regard.
A number of signaling molecules known to associate
with FAK in focal adhesions such as paxillin (Richardson
and Parsons, 1996) and Cas (Polte and Hanks, 1995) rep-
resent potential downstream targets for FAK. However,
further work will be required to elucidate this pathway. A
critical role for FAK in growth factor induction of MAP
kinase activity is likely to explain the loss of cell cycle pro-
gression when FAK is inhibited (Gilmore and Romer,
1996), and may be important in the embryonic lethality of
FAK2/2 mouse embryos. MAP kinase has been demon-
strated to regulate cell migration through the enhance-
ment of myosin light chain phosphorylation (Klemke et al.,
1997). Thus, the requirement for FAK activity in the effi-
cient activation of MAP kinase could also be related to ef-
fects of FAK on cell motility, as demonstrated in a number
of studies (Ilic et al., 1995; Cary et al., 1996; Gilmore and
Romer, 1996).
Previous studies have shown that FAK and src family ki-
nase function in a highly cooperative manner (Cobb et al.,
1994; Schlaepfer and Hunter, 1994, 1997). Thus, the Y397F
mutant of FAK that does not bind c-src functions as a
strong dominant negative for FAK, whereas the K454R ki-
nase defective mutant that still binds c-src does not (Cary
et al., 1996; Schlaepfer and Hunter, 1997). Our result that
the Y397F but not the K454R mutant blocks FAK signal-
ing in adherent cells is, therefore, consistent with previous
studies, and most likely reflects the ability of the K454R
mutant to be phosphorylated by other kinases (or endoge-
nous FAK), enabling it to bind c-src. Therefore, it is likely
that src family kinases make a critical contribution to the
effects described here, either by activating FAK or by di-
rectly phosphorylating key downstream substrates.
Third, our data implicate FAK in oncogenic transforma-
tion by v-src. Constitutive FAK activation is not sufficient
to transform cells but substantially potentiates anchorage-
independent growth induced by v-ras without altering
growth of adherent ras cells. It is important to note in this
regard that while ras-transformed cells form colonies in
soft agar, their growth is markedly slower in suspension
than when adherent. v-src, which induces constitutive acti-
vation of FAK (Kanner et al., 1990; Guan and Shalloway,
1992), as well as activation of ras stimulates MAP kinase in
an adhesion-independent manner. MAP kinase activation
by v-src was inhibited by dominant negative FAK in both
adherent and suspended cells, indicating that FAK con-
tributes to v-src induction of MAP kinase under both con-
ditions.
Tumorigenesis is thought to be a multistep process. De-
regulation of FAK could greatly enhance the tumorigenic-
ity of transformed cells in vivo via effects on both growth
and motility. Anchorage-independent growth is the in
vitro characteristic that correlates most closely with in vivo
tumorigenicity (Freedman and Shin, 1974). Motility plays
a critical role in invasion and metastasis. FAK expression
correlates with motility in human melanoma cell lines
(Akasaka et al., 1995), and its activity and expression in-
crease in metastatic tumors (Weiner et al., 1993; Owens
et al., 1995). Elevated FAK expression also correlated
with the invasive potential of tumors (Owens et al., 1995).
These data support the notion that elevation of FAK lev-
els or activity can contribute to progression of human tu-
mors.
In mammalian cells, cellular functions such as growth,
gene expression, and migration are controlled by multiple
external stimuli, and understanding how these inputs are
integrated is an important goal in cell biology. Our results
identify a point of intersection between integrin and
growth factor pathways, and identify FAK as a key com-
ponent of the integrin but not the growth factor arm of this
pathway. These data also represent the first example
where oncogene function can be understood in terms of
specific activation of an integrin-mediated event. There-
fore, this work contributes to our understanding of both
normal cell regulation and the subversion of these path-
ways in cancer.
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